L-Carnitine L-Tartrate 500MG + Methylcobalamin 1500MCG + Folic Acid 1.5MG Tablets is a multi component combination tablet of solid oral dosage form that combines L-Carnitine L-Tartrate with two lower strength vitamin ingredients into one tablet. The formulation and processing have to address a significant component ratio difference: 1,430:1,18:1, so there is a need to understand blending, fill-flow and tableting implications of this ratio before formulating. This product is suitable for those interested in adding a combination product to a PCD Pharma Franchise product range, delivered by manufacturing and QC operations.
The combination also needs to be balanced for the physical characteristics of all three ingredients. The volume of L-Carnitine L-Tartrate is substantially higher than the two active ingredients and this constitutes the bulk of the tablet blend, whereas the methylcobalamin and folic acid need to be evenly distributed.
Formulation Development The first step in formulation development is characterization of L-Carnitine L-Tartrate, methylcobalamin, and folic acid. How the powder will respond during processing will depend on a variety of factors, including particle size, bulk density, flow properties and how sensitive to moisture the material is.
The excipients are used according to their technological property. The excipients can be used for facilitate powder flow, binding, lubrication, compression, and stability of the tablet, based on their design.
We use a high active load of 500MG L-Carnitine L-Tartrate to optimise the size, density and compressibility of our tablet. We also use the significant doses of methylcobalamin (1500MCG) and folic acid (1.5MG), which require special control to avoid concentration variations.
All raw materials are supplied as per formulation approved specification. All raw materials are identified, weighed and documented to ensure traceability prior to mixing into the product.
One of the main considerations of this product format is the distribution of the methylcobalamin and folic acid in the wider L-Carnitine L-Tartrate-based mix. The methylcobalamin and folic acid are present at a much smaller dose so a controlled premix can assist in their distribution.
What if the alternative premixes are not by themselves, i.e., a singular premix? Or, how to perform an on line premix? For whichever reason, the methylcobalamin and folic acid could initially be blended, in some proportion and with a number of the powder premix, through a controlled dilution approach before being dosed into the rest of the formulation.
Mixing sequence, amount of equipment loaded, and time of blending are determined at the process development stage. These are maintained to prevent segregation, not just to optimize uniformity.
Representative blend samples may be analyzed by appropriate analytical methods. Sampling at different points throughout the batch can give information about the homogeneity of the low-dose components prior to compression.
The relatively high quantity of L-Carnitine L-Tartrate means that powder-flow and compression behavior have to be taken into account. The formulation has to flow well through processing equipment, while preserving good blend uniformity.
Particle-size distribution, bulk density and lubrication are taken into account during formulation optimization. The aim is to create a formulation that not only guarantees precise powder feeding but also results in tablets with reproducible physical properties.
Compression The control is exercised over machine speed, force of compression, tooling arrangement and powder feed parameters during the compression cycle. Testing during compression may consist of checking the weight, thickness, friability and hardness of the tablet.
They can also spot visible signs of physical abnormalities, such as capping, lamination, sticking or edges. The compression process is fine-tuned to ensure it produces a package of adequate mechanical strength for handling and packaging and of the correct disintegration/dissolution properties.
9.4.3. Physical/Preliminary inspection Quality assessment of the finished tablets is carried out on all three components of the formulation. Analytical methods are devised/devised to allow specific identification and quantification of L-Carnitine L-Tartrate, methylcobalamin, and folic acid respectively in the finished product, in conformance with the approved specification.
Therefore, analytical sensitivity is a key factor because methylcobalamin is present at low concentration. Properly qualified sample preparation and analytical procedures support the production of robust results for the microgram component.
For finished tablets testing may be carried out for assay, uniformity, average weight, weight variation, disintegration, dissolution, friability, and relevant test parameters as specified in the product specification.
Representative sampling is critical for multi-component products. Good documentation of raw-material testing, dispensing, premix making, blending, compression and lab work ensures accountability through each stage of production.
Stability testing takes into account the overall behavior of the three ingredients in the tablet matrix L-Carnitine L-Tartrate, methylcobalamin and folic acid. Due to the potential differences in sensitivities to environmental conditions, the formulation and the packaging are taken into account.
Packaging Systems Appropriate blister, strip, and other pharmaceutical packaging systems can be assessed considering the amount of protection needed for the formulation with respect to light, moisture and the environment. Seal suitability and material compatibility should also be taken into consideration in order to preserve the quality of the tablet during storage.
The stability studies may include assay, appearance, physical integrity, dissolution and other relevant quality characteristics at specified time points. The information obtained is used to evaluate the storage conditions and proposed shelf-life of the finished product in accordance with the relevant specification.
For such pharma companies building a nutritional & vitamin supplements portfolio, L-Carnitine L-Tartrate 500MG + Methylcobalamin 1500MCG + Folic Acid 1.5MG Tablets is included in the best quality PCD Pharma Franchise range of the formulations. This medicine are designed with a decided premix manufacturing, compression, the duality test of the analytically proved formulation and well protection packaging.
In summary, the composition incorporates a relatively high-dose nutritional agent along with two lower-strength vitamin ingredients. Its manufacture requires very precise dispensing, premix specification and creation, blend consistency, powder-flow management, compression precision, sensitive analytical methodology, stability testing and packaging matching. Stringent control throughout these parameters will allow reproducible production and finished-product consistency.
L-Carnitine L-Tartrate 500mg with Methylcobalamin 1500mcg and Folic Acid 1.5mg Tablets for formulation, quality, stability and PCD Pharma.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech